Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICI) (e.g., anti-programmed death-ligand 1/programmed death-1 (anti-PD-L1/PD-1)) are among the most commonly used therapies (alone and in combination) for ccRCC particularly in advanced metastatic patients [8–10]. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.